| 10.35 -0.27 (-2.54%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.69 | 1-year : | 14.93 |
| Resists | First : | 11.72 | Second : | 12.78 |
| Pivot price | 10.63 |
|||
| Supports | First : | 10.01 | Second : | 8.32 |
| MAs | MA(5) : | 10.43 |
MA(20) : | 10.73 |
| MA(100) : | 10.53  |
MA(250) : | 8.79 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 28.7 |
D(3) : | 25.6 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 13.25 | Low : | 5.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FENC ] has closed above bottom band by 18.3%. Bollinger Bands are 63.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.67 - 10.73 | 10.73 - 10.78 |
| Low: | 9.98 - 10.06 | 10.06 - 10.12 |
| Close: | 10.23 - 10.35 | 10.35 - 10.45 |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Thu, 01 Oct 2026
Award shares leave restriction as Fennec Pharmaceuticals (FENC) CFO acquires 1,703 shares. - Stock Titan
Thu, 01 Oct 2026
Medical chief acquires 168 awarded shares at Fennec Pharmaceuticals (FENC), holding 9,687 directly. - Stock Titan
Thu, 01 Oct 2026
Commercial chief acquires 168 shares released from restriction at Fennec Pharmaceuticals (FENC). - Stock Titan
Fri, 14 Aug 2026
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall Street
Fri, 14 Aug 2026
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 54.3 (%) |
| Shares Short | 532 (K) |
| Shares Short P.Month | 609 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | -5.5 % |
| Operating Margin | 9.7 % |
| Return on Assets (ttm) | -1.2 % |
| Return on Equity (ttm) | -18.6 % |
| Qtrly Rev. Growth | 85.1 % |
| Gross Profit (p.s.) | 1.58 |
| Sales Per Share | 1.68 |
| EBITDA (p.s.) | -0.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -86.26 |
| PEG Ratio | 1.4 |
| Price to Book value | 8.55 |
| Price to Sales | 6.12 |
| Price to Cash Flow | -177.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|